leflunomide has been researched along with Benign Neoplasms in 8 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Effectiveness of leflunomide renders it a potent treatment option in rheumatoid arthritis." | 8.87 | Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. ( Behrens, F; Burkhardt, H; Koehm, M, 2011) |
| "Effectiveness of leflunomide renders it a potent treatment option in rheumatoid arthritis." | 4.87 | Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. ( Behrens, F; Burkhardt, H; Koehm, M, 2011) |
| "To evaluate the clinical feasibility and pharmacologic behavior of the platelet-derived growth factor (PDGF) tyrosine kinase inhibitor SU101, administered on a prolonged, intermittent dosing schedule to patients with advanced solid malignancies." | 2.69 | Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. ( Baker, SD; Cropp, G; Drengler, R; Eckardt, JR; Eckhardt, SG; Hammond, L; Hannah, AL; Kraynak, MA; Kuhn, JG; Moczygemba, J; Rizzo, J; Rowinsky, EK; Smith, L; Sweeney, KR; Thurman, A; Villalona-Calero, MA; Von Hoff, DD; Weiss, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Jin, R | 1 |
| Liu, B | 1 |
| Liu, X | 1 |
| Fan, Y | 1 |
| Peng, W | 1 |
| Huang, C | 1 |
| Marcus, A | 1 |
| Sica, G | 1 |
| Gilbert-Ross, M | 1 |
| Liu, Y | 1 |
| Zhou, W | 1 |
| Zhang, C | 1 |
| Chu, M | 1 |
| Astin, JW | 1 |
| Jamieson, SM | 1 |
| Eng, TC | 1 |
| Flores, MV | 1 |
| Misa, JP | 1 |
| Chien, A | 1 |
| Crosier, KE | 1 |
| Crosier, PS | 1 |
| Behrens, F | 1 |
| Koehm, M | 1 |
| Burkhardt, H | 1 |
| Hudes, G | 1 |
| Eckhardt, SG | 1 |
| Rizzo, J | 1 |
| Sweeney, KR | 1 |
| Cropp, G | 1 |
| Baker, SD | 1 |
| Kraynak, MA | 1 |
| Kuhn, JG | 1 |
| Villalona-Calero, MA | 1 |
| Hammond, L | 1 |
| Weiss, G | 1 |
| Thurman, A | 1 |
| Smith, L | 1 |
| Drengler, R | 1 |
| Eckardt, JR | 1 |
| Moczygemba, J | 1 |
| Hannah, AL | 1 |
| Von Hoff, DD | 1 |
| Rowinsky, EK | 1 |
3 reviews available for leflunomide and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Leflunomide: A promising drug with good antitumor potential.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; En | 2018 |
Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses.
Topics: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheuma | 2011 |
1 trial available for leflunomide and Benign Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Growth Inhibitors; Humans; Immunohistoche | 1999 |
4 other studies available for leflunomide and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis.
Topics: Enzyme Inhibitors; Humans; Immune Tolerance; Leflunomide; Neoplasm Metastasis; Neoplasms | 2021 |
An in vivo antilymphatic screen in zebrafish identifies novel inhibitors of mammalian lymphangiogenesis and lymphatic-mediated metastasis.
Topics: Animals; Antineoplastic Agents; Cinnarizine; Endothelial Cells; Female; Flunarizine; Humans; Isoxazo | 2014 |
Signaling inhibitors in the clinic: new agents and new challenges.
Topics: Clinical Trials, Phase I as Topic; Growth Inhibitors; Humans; Isoxazoles; Leflunomide; Neoplasms; Ph | 1999 |